Stealth BioTherapeutics Shares Rally following FDA Orphan Drug Designation To Elamipretide For Duchenne muscular dystrophy (DMD)

Stealth BioTherapeutics Corp (NASDAQ:MITO) received Orphan Drug Designation to Elamipretide from the United States Food and Drug Administration (FDA) for the treatment of patients with Duchenne muscular dystrophy (DMD).

Reenie McCarthy, Chief Executive Officer, said, ”We are pleased that the FDA has recognized the high unmet need for innovative treatments for DMD, We look forward to further discussions with the FDA regarding our development initiatives, which we hope will bring new options to patients suffering from this devastating disease.”